Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Breast Cancer Research
  • View item
  • Home
  • ICR Divisions
  • Breast Cancer Research
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Circulating microRNA-652-3p as a biomarker of regorafenib resistance in metastatic colorectal cancer patients

Thumbnail
View/Open
Accepted version (30.95Mb)
Date
2020-09-30
ICR Author
Hedayat, Somaieh
Author
Valeri, N
Hedayat-Husseyin, S
Type
Thesis or Dissertation
Metadata
Show full item record
Abstract
MicroRNAs (miRNAs) are small non-coding RNAs involved in cell homeostasis. MiRNAs dysregulation has been linked with activation of oncogenic pathways, cancer progression and clinical outcome in metastatic colorectal cancer (mCRC). Chemo-refractory mCRC patients are often treated with regorafenib, a multi-tyrosine kinase inhibitor with anti-angiogenic effect. Given the limited clinical benefits of regorafenib in unselected patient populations, there is an unmet need for better patients' stratification and identification of mechanisms of resistance. Serial liquid and tissue biopsies were obtained in 41 patients treated with regorafenib for chemo-refractory mCRC in the context of a phase II clinical trial (PROSPECT-R). Liquid biopsies were also obtained from an additional cohort (n=85) of mCRC patients treated with regorafenib. MiRNA profiling was performed and significant deregulated miRNAs were validated with digital droplet (dd) PCR in serum, plasma, patient-derived organoids (PDOs) and by In Situ Hybridization (ISH) in matching tissue biopsies, including up-regulation of miRNA-652-3p that was associated with poor progression free survival (PFS) and overall survival (OS). The same findings were confirmed in the validation cohort. RNA-sequencing analysis of miRNA-652-3p over-expressing organoids, showed downregulation of phosphoserine aminotransferase (PSAT1) a key enzyme involved in the serine synthesis pathway. PSAT1 was validated as a miRNA-652-3p direct target and in vivo experiments confirmed that PSAT1 over-expression could restore sensitivity to regorafenib. Our data suggest the miRNA-652-3p may be used as a prognostic/predictive biomarker for patients' stratification for regorafenib treatment and provide biological mechanisms that might explain regorafenib acquired resistance.
URI
https://repository.icr.ac.uk/handle/internal/4551
Collections
  • Breast Cancer Research
  • Molecular Pathology
Subject
Theses, Doctoral
Colorectal Cancer - Therapy
Colorectal Cancer - Molecular Biology
Research team
Functional Genomics
Language
eng
License start date
2020-09-30
Citation
2020
Publisher
Institute of Cancer Research (University Of London)

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.